Arrowgrass Capital Partners (US)’s Merck MRK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q4
$9.1M Hold
104,800
2.39% 9
2019
Q3
$8.42M Hold
104,800
0.63% 43
2019
Q2
$8.38M Sell
104,800
-282,960
-73% -$21.7M 0.2% 138
2019
Q1
$30.8M Buy
387,760
+282,960
+270% +$21.2M 0.91% 22
2018
Q4
$7.64M Buy
+104,800
New +$7.4M 0.28% 111
2018
Q1
Sell
-332,845
Closed -$17.9M 361
2017
Q4
$17.9M Buy
332,845
+329,517
+9,901% +$18.3M 0.17% 143
2017
Q3
$20.3M Sell
3,328
-5,703
-63% -$346K 0.15% 170
2017
Q2
$55.2M Buy
9,031
+5,915
+190% +$360K 0.42% 58
2017
Q1
$18.9M Buy
3,116
+1,984
+175% +$120K 0.19% 151
2016
Q4
$6.36M Buy
1,132
+206
+22% +$12.1K 0.07% 237
2016
Q3
$5.52M Sell
926
-397
-30% -$23.2K 0.07% 201
2016
Q2
$7.27M Sell
1,323
-2,268
-63% -$121K 0.08% 153
2016
Q1
$18.1M Buy
3,591
+2,085
+138% +$102K 0.22% 80
2015
Q4
$7.59M Sell
1,506
-71
-5% -$3.58K 0.09% 128
2015
Q3
$7.43M Sell
1,577
-2,845
-64% -$151K 0.14% 120
2015
Q2
$24M Buy
4,422
+3,241
+274% +$182K 0.36% 52
2015
Q1
$6.48M Sell
1,181
-20,617
-95% -$1.17M 0.1% 123
2014
Q4
$1.18M Buy
+21,798
New +$1.21M 0.02% 292

Other funds holding MRK

Arrowgrass Capital Partners (US)'s MRK Position: Q1 2018 in Review

Arrowgrass Capital Partners (US) sold out of Merck (MRK) in Q1 2018, closing a stake of 159,612 shares — an estimated $8.57M sold.

Arrowgrass Capital Partners (US) first reported a position in MRK in Q4 2013 and held it in 16 quarters. The position peaked at $15.3M in Q4 2016. 1,992 funds tracked by Wall St. Rank hold MRK as of Q1 2018.

  • Arrowgrass Capital Partners (US) reported no remaining Merck position as of Q1 2018 after selling out during the quarter.
  • Arrowgrass Capital Partners (US) sold 159,612 Merck shares in Q1 2018, an estimated $8.57M.
  • Arrowgrass Capital Partners (US) first reported a position in Merck in Q4 2013 and held it in 16 quarters.
  • Arrowgrass Capital Partners (US)'s Merck position peaked at $15.3M in Q4 2016.
  • 1,992 funds tracked by Wall St. Rank held Merck as of Q1 2018.

Based on Arrowgrass Capital Partners (US)'s 13F filing for Q1 2018, filed 15 May 2018.